ASH 2020 | PV highlights at ASH 2020
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, offers his highlights from polycythemia vera (PV) data presented at ASH 2020. PTG-300, a hepcidin mimetic that acts by preventing iron release in erythropoiesis, represents a promising means for eliminating the need for phlebotomy in PV and improves the symptoms of iron deficiency. Dr Bose also discusses data from the 5-year update on ropeginterferon alpha-2b in PV patients, which showed sustained efficacy and a good toxicity profile. Additionally, he offers key takeaways from data presented on the observational REVEAL study (NCT02252159), which aims to provide real-world data on the clinical management of PV in the US. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Prithviraj Bose, MD, has received honoraria from Incyte Corporation and Celgene Corporation (now BMS); has received consulting fees from Incyte Corporation, Celgene Corporation, Blueprint Medicines, CTI BioPharma and Kartos Therapeutics; and has received research funding from Incyte Corporation, Celgene Corporation, Blueprint Medicines, CTI BioPharma, Kartos Therapeutics, Constellation Pharmaceuticals, Astellas, Pfizer, NS Pharma and Promedior.
